These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 8505149)
41. Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding. Clayton LK; Sieh M; Pious DA; Reinherz EL Nature; 1989 Jun; 339(6225):548-51. PubMed ID: 2543930 [TBL] [Abstract][Full Text] [Related]
42. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. Yang QE; Stephen AG; Adelsberger JW; Roberts PE; Zhu W; Currens MJ; Feng Y; Crise BJ; Gorelick RJ; Rein AR; Fisher RJ; Shoemaker RH; Sei S J Virol; 2005 May; 79(10):6122-33. PubMed ID: 15857997 [TBL] [Abstract][Full Text] [Related]
43. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates. Pinter A; Honnen WJ; Racho ME; Tilley SA AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556 [TBL] [Abstract][Full Text] [Related]
44. Synthetic peptides and anti-peptide antibodies as probes to study interdomain interactions involved in virus assembly: the envelope of the human immunodeficiency virus (HIV-1). Neurath AR; Strick N; Jiang S Virology; 1992 May; 188(1):1-13. PubMed ID: 1373549 [TBL] [Abstract][Full Text] [Related]
45. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120. Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828 [TBL] [Abstract][Full Text] [Related]
46. Human immunodeficiency virus gp120 binding C'C" ridge of CD4 domain 1 is also involved in interaction with class II major histocompatibility complex molecules. Moebius U; Clayton LK; Abraham S; Diener A; Yunis JJ; Harrison SC; Reinherz EL Proc Natl Acad Sci U S A; 1992 Dec; 89(24):12008-12. PubMed ID: 1465431 [TBL] [Abstract][Full Text] [Related]
47. Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity. Xiao X; Phogat S; Shu Y; Phogat A; Chow YH; Wei OL; Goldstein H; Broder CC; Dimitrov DS Vaccine; 2003 Oct; 21(27-30):4275-84. PubMed ID: 14505910 [TBL] [Abstract][Full Text] [Related]
48. Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus type 1 infection through interaction with CD4. Benjouad A; Chapuis F; Fenouillet E; Gluckman JC Virology; 1995 Jan; 206(1):457-64. PubMed ID: 7831801 [TBL] [Abstract][Full Text] [Related]
50. Multiple effects of CD4 CDR3-related peptide derivatives showing anti-HIV-1 activity on HIV-1 gp120 functions. Ohki K; Kimura T; Jones IM; Morita F; Ikuta K Vaccine; 1994 Mar; 12(4):343-50. PubMed ID: 8178557 [TBL] [Abstract][Full Text] [Related]
51. The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4. Landau NR; Warton M; Littman DR Nature; 1988 Jul; 334(6178):159-62. PubMed ID: 3260352 [TBL] [Abstract][Full Text] [Related]
53. Ligation of human CD4 interferes with antigen-induced activation of primary T cells. Marschner S; Hünig T; Cambier JC; Finkel TH Immunol Lett; 2002 Jun; 82(1-2):131-9. PubMed ID: 12008044 [TBL] [Abstract][Full Text] [Related]
54. Detection of anti-CD4 autoantibodies in the sera of HIV-infected patients using recombinant soluble CD4 molecules. Chams V; Jouault T; Fenouillet E; Gluckman JC; Klatzmann D AIDS; 1988 Oct; 2(5):353-61. PubMed ID: 3146263 [TBL] [Abstract][Full Text] [Related]
55. HIV gp120 inhibits T cell activation by interfering with expression of costimulatory molecules CD40 ligand and CD80 (B71). Chirmule N; McCloskey TW; Hu R; Kalyanaraman VS; Pahwa S J Immunol; 1995 Jul; 155(2):917-24. PubMed ID: 7541827 [TBL] [Abstract][Full Text] [Related]
56. Competition of HLA-DR and a beta 2 domain peptide for HIV envelope glycoprotein gp120 binding to CD4. Autiero M; Houlgatte R; Martin M; Auffray C; Guardiola J; Piatier-Tonneau D Int Immunol; 1995 Feb; 7(2):191-7. PubMed ID: 7734415 [TBL] [Abstract][Full Text] [Related]
57. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies. Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663 [TBL] [Abstract][Full Text] [Related]
58. A functional, discontinuous HIV-1 gp120 C3/C4 domain-derived, branched, synthetic peptide that binds to CD4 and inhibits MIP-1alpha chemokine binding. Howie SE; Fernandes ML; Heslop I; Hewson TJ; Cotton GJ; Moore MJ; Innes D; Ramage R; Harrison DJ FASEB J; 1999 Mar; 13(3):503-11. PubMed ID: 10064617 [TBL] [Abstract][Full Text] [Related]
59. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. Pantophlet R; Ollmann Saphire E; Poignard P; Parren PW; Wilson IA; Burton DR J Virol; 2003 Jan; 77(1):642-58. PubMed ID: 12477867 [TBL] [Abstract][Full Text] [Related]
60. Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding. Schnittman SM; Lane HC; Roth J; Burrows A; Folks TM; Kehrl JH; Koenig S; Berman P; Fauci AS J Immunol; 1988 Dec; 141(12):4181-6. PubMed ID: 3264307 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]